Publications by authors named "Robel Papotti"

Claim this Profile
M
Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemia.
Filippo Vit, Tamara Bittolo, Antonella Zucchetto, Robel Papotti, Erika Tissino

Leukemia· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new digital droplet PCR method for looking at epigenetics in diffuse large B-cell lymphomas: The role of BMI1, EZH2, and USP22 genes.
Alessio Lusci Gemignani, Robel Papotti, Riccardo Bomben, Valter Gattei, Samantha Pozzi

Int J Lab Hematol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.
Federico Pozzo, Gabriela Forestieri, Filippo Vit, Giulia Ianna, Erika Tissino, Robel Papotti

Leukemia· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experience.
Riccardo Bomben, Antonella Zucchetto, Roberta Laureana, Annalisa Chiarenza, Jacopo Olivieri, Robel Papotti

Hemasphere· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of monoclonal B-cell expansion and intraclonal diversification despite virus eradication in patients affected by hepatitis C virus-associated lymphoproliferative disorders.
Cesare Mazzaro, Marcella Visentini, Laura Gragnani, Filippo Vit, Erika Tissino, Robel Papotti

Br J Haematol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicopathological, cytogenetic, and molecular profiles of primary cutaneous diffuse large B-cell lymphomas.
Silvia Uccella, Gaia Goteri, Antonino Maiorana, Valentina Donati, Maria Grazia Tibiletti, Robel Papotti

Hum Pathol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study.
Riccardo Bomben, Francesca Maria Rossi, Filippo Vit, Tamara Bittolo, Antonella Zucchetto, Robel Papotti

Leukemia· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IgM-secreting diffuse large B-cell lymphoma: results of a multicentre clinicopathological and molecular study.
M Christina Cox, Luigi Marcheselli, Giorgia Scafetta, Carlo Visco, Stefan Hohaus, Robel Papotti

Leukemia· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting.
Stefania Bettelli, Raffaella Marcheselli, Samantha Pozzi, Luigi Marcheselli, Robel Papotti

Leuk Res· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma.
Raffaella Marcheselli, Alessia Bari, Tamar Tadmor, Luigi Marcheselli, Maria Christina Cox, Robel Papotti

Hematol Oncol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis